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Abstract
Context—Regulation of fat mass appears to be associated with immune functions. Studies of 
knockout mice show that endogenous interleukin (IL)-6 can suppress mature-onset obesity.
Objective—To systematically investigate associations of single nucleotide polymorphisms 
(SNPs) near the IL-6 (IL6) and IL-6 receptor (IL6R) genes with body fat mass, in support for our 
hypothesis that variants of these genes can be associated with obesity.
Design and Study Subjects—The Gothenburg Osteoporosis and Obesity Determinants 
(GOOD) study is a population-based cross-sectional study of 18-20 years old men (n=1 049), from 
the Gothenburg area (Sweden). Major findings were confirmed in two additional cohorts 
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consisting of elderly men from the Osteoporotic Fractures in Men (MrOS) Sweden (n=2 851) and 
MrOS US (n=5 611) multicenter population-based studies.
Main Outcome—The genotype distributions and their association with fat mass in different 
compartments, measured with dual-energy X-ray absorptiometry (DXA).
Results—Out of 18 evaluated tag single nucleotide polymorphisms (SNPs) near the IL6 and 
IL6R genes, a recently identified SNP rs10242595 G/A [minor allele frequency (MAF) = 29%] 3′ 
of the IL6 gene was negatively associated with the primary outcome total body fat mass (effect 
size -0.11 standard deviation (SD) units/A allele, P=0.02). This negative association with fat mass 
was also confirmed in the combined MrOS Sweden and MrOS US cohorts (effect size -0.05 SD 
units/A allele; P=0.002). When all three cohorts were combined (n= 8 927, Caucasian subjects), 
rs10242595*A showed a negative association with total body fat mass (effect size -0.05 SD 
units/A allele, P<0.0002). Furthermore, the rs10242595*A was associated with low body mass 
index [(BMI, effect size -0.03, P<0.001)] and smaller regional fat masses. None of the other SNPs 
investigated in the GOOD study were reproducibly associated with body fat.
Conclusions—The IL6 gene polymorphism rs10242595*A is associated with decreased fat 
mass in three combined cohorts of 8 927 Caucasian men.
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Introduction
Interleukin-6 (IL-6) is a cytokine that mainly stimulates immune responses, such as B cell 
proliferation and acute phase production by the liver (1). The immune modulating effects of 
IL-6 have been shown with the IL-6 neutralizing drug tocilizumab which has beneficial 
effects on autoimmune diseases such as juvenile and adult rheumatoid arthritis (2, 3). 
However, IL-6 also has some anti-inflammatory properties such as inhibition of the effects 
of tumor necrosis factor-alpha (TNFα) (4, 5).
The IL-6 receptor (IL-6R) belongs to the type I cytokine receptor group of transmembrane 
receptors and is expressed on the cell surface. The IL-6R complex consists of two parts, the 
ligand binding IL-6R (also known as IL-6Rα, encoded by the IL6R gene) and the IL-6 signal 
transducer (previously designated gp130, encoded by IL6ST gene). The IL-6R specifically 
binds IL-6 and is expressed on few cell types including immune cells and hepatocytes. 
IL6ST is much less specific than the IL-6R, as it is a component of several cytokine 
receptors, and is expressed on the surface of most cell types (6). It has been claimed that 
pro-inflammatory and other pathophysiological effects of IL-6 to a large extent are exerted 
via so called trans-signaling, i.e. when a complex between IL-6 and a soluble isoform of the 
IL-6R is activating membrane bound IL-6ST in various cell types (6). The physiological 
effects of IL-6 have been suggested to be exerted via the classic route, with free IL-6 acting 
on membrane bound IL-6R/IL6-ST dimers (6).
Recent results indicate that IL-6, in addition to regulating various immune functions, also 
affects metabolic functions, including fat metabolism. IL-6 is one of several so called 
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adipokines which are produced and released by white adipose tissue, and has been assumed, 
together with other adipokines, to contribute to obesity related metabolic and cardiovascular 
disturbances (7). On the other hand, IL-6 is released from working skeletal muscle in the 
absence of substantial release of other pro-inflammatory cytokines such as TNF-α. It has 
been suggested that IL-6 in this context exerts beneficial effects on the carbohydrate and fat 
metabolism as well as the exercise capacity (5, 8). In addition, IL-6 knockout mice as well 
as IL-6/IL-1 double knockout mice get obese, indicating that endogenous IL-6 exerts 
beneficial effects on fat mass in healthy individuals (8-10). The obesity preventing 
mechanism by IL-6 is unknown, but there are indications that endogenous IL-6 is of 
importance for leptin sensitivity in healthy individuals, and that the site of its action is in the 
hypothalamus (10-14). More recent data are in line with effects by IL-6 via the 
paraventricular nucleus of the hypothalamus (15). This in turn may lead to activation of the 
sympathetic nerve system and increased energy expenditure (16, 17).
In early studies, there was an association between a supposedly functional polymorphism of 
the IL6 gene promoter, the -174G/C single nucleotide exchange (rs1800795), described by 
Fishman et al. (18), and body mass index (BMI) as reported by for instance Grallert et al 
(19). However, the association with BMI did not reach the level of significance in two meta-
analyses on over 25 000 subjects per study (20, 21). Nevertheless, in a recent study of more 
than 3 000 individuals, an association between variants in the IL6 gene and BMI was shown 
(21). Moreover, there was an association between rs1800795 and total and regional fat 
masses as determined by DXA in a cohort with 3 014 elderly men (22). A possible reason 
for the above described discrepancy could be not yet clarified interference by other 
parameters such as gender, age, cohort and other gene polymorphisms. For example, the 
studied SNPs may be in linkage disequilibrium (LD) with yet unknown functional 
polymorphisms in the IL6 which are the primary regulators of body fat (23).
In the IL6R there is a non-synonymous SNP (rs8192284, also called rs2228145), that seems 
to affect the proteolytic cleavage of a part of the extracellular domain of the IL-6R. This 
SNP has been associated with BMI and blood glucose in some, but not all studies, possibly 
due to differences between ethnic groups (24-28). In summary, the issue of possible 
associations between IL-6 system gene polymorphisms and obesity does not seem to be 
settled.
Based on the obesity observed in IL-6 knockout mice (IL6-/-) (8-10), the aim of the present 
study was to carefully investigate whether polymorphisms in the IL-6 system genes are 
associated with body fat mass in humans. We used several means to obtain novel 
information as compared with earlier literature. We used a gene-tagging approach to find 
common genetic variants in IL6 and IL6R, the two genes which are important for the unique 
biological effects of IL-6. The tag SNPs were investigated in relation to total body fat mass 
measured by dual energy X-ray absorbtiometry (DXA), a more specific measure than BMI 
(29). To increase statistical power, three different populations (8 927 subjects in total) which 
were relatively homogeneous for age, gender and ethnicity were investigated.
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Subjects and Methods
Study subjects: young adult men
The population-based Gothenburg Osteoporosis and Obesity Determinants (GOOD) study 
was initiated to determine environmental and genetic factors involved in the regulation of 
bone and fat mass. Study subjects were randomly identified using national population 
registers, contacted by telephone, and asked to participate in this study. Men aged 18 – 20 
years from the greater Gothenburg area in Sweden were approached. There were no 
specified exclusion criteria. Almost half (49%) of the study candidates agreed to participate 
and were enrolled (n = 1 068, mean age 18.9 ± 0.6 yr) (30, 31). Informed consent was 
obtained from all study participants. The study was approved by the ethics committee at the 
University of Gothenburg.
A total of 1 049 subjects with both successful genotyping and available data on body 
composition (Table 1) were included in the initial screening of variants in the IL6 and IL6R 
genes and their association with total body fat mass.
Study subjects: elderly men
The major findings in the initial screening study were replicated in two large cohorts of 
elderly men [Osteoporotic Fractures in Men (MrOS) Sweden and MrOS US] with available 
data on body composition (Table 1). Study subjects of the population-based MrOS Sweden 
cohort (n = 3 014; men aged 69–81 yr) were randomly identified using national population 
registers, contacted, and asked to participate (32). A total of 2 851 subjects with both 
successful genotyping and available data on body composition were included in the first 
replication analysis.
The MrOS US cohort consists of 5 995 community-dwelling, ambulatory men aged ≥65 
years (33, 34). A total of 5 611 MrOS US subjects with both successful genotyping and 
available data on body composition (Table 1) were included in this study.
Assessment of body composition
In the GOOD cohort, lean tissue mass and fat masses for total body, arm, leg, and trunk 
were determined by using DXA (Lunar Prodigy DXA, GE Lunar Corp., Madison, WI). In 
the MrOS Sweden cohort, lean tissue mass and total fat mass were determined using the 
Lunar Prodigy DXA (n = 1 997) for subjects investigated in Malmö (n = 998) and Uppsala 
(n = 999) or the Hologic DXA Hologic QDR 4500/A-Delphi (Hologic, Whaltman, MA) (n = 
953) for subjects investigated in Gothenburg. The QDR 4500 Hologic machine was also 
used at all six MrOS US clinical sites.
Assessment of covariates
A standardized questionnaire was used to collect information about amount of physical 
activity and smoking. In the GOOD cohort, physical activity was assessed as hours of 
physical activity per week, as previously described (31). In the MrOS Sweden cohort 
physical activity was the subject's average total daily walking distance (in km), including 
both walking as a means of exercise and leisure, and as a means of outdoor transportation in 
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activities of daily life (32). In the MrOS US cohort, physical activity was assessed as the 
self-reported number of city blocks walked each day, including both walking as a means of 
exercise and walking as a part of daily routine. In order to be able to merge the measure of 
physical activity for the MrOS Sweden and MrOS US into a common variable it was 
assumed that 1 city block = 200 meters.
Genotyping
In all three cohorts conducted, genotyping was completed using genomic DNA prepared 
from whole blood.
GOOD cohort—Altogether 19 SNPs with MAF≥5% in the IL6 (n=9, Table 2) and the 
IL6R (n=10, Table 1S) were selected from HapMapData Rel 21/phasell (http://
hapmap.ncbi.nlm.nih.gov/) using a pair-wise correlation method (r2≥0.80) including the 
sequence 10 kb upstream and 5 kb downstream of each gene. The SNPs were genotyped 
using the GoldenGate™ assay (35) from Illumina Inc (San Diego CA, USA). The 
genotyping was performed by the SNP Technology Platform in Uppsala, Sweden 
(www.genotyping.se). Of the genotyped SNPs, all 19 had a genotype call rate of ≥99 % in 
the study subjects. One of these SNPs, rs12700386, was not polymorphic, leaving 18 SNPs 
for further analysis. The reproducibility of the genotyping was 100% according to duplicate 
analysis of 5% of the samples. There were no deviations from HWE for these markers 
(P>0.05, Table 2 and Table 1S).
MrOS Sweden cohort—rs10242595 in the IL6 and rs4075015 in the IL6R were analyzed 
using the Sequenom MassARRAY platform (San Diego, CA, USA). The overall call rate 
was ≥98 %, and 167 samples were run in duplicates with 100% genotyping concordance 
rate. The SNPs rs10242595 and rs4075015 were both in HWE.
MrOS US cohort—Genotyping was performed using TaqMan® technology (Applied 
Biosystems, Foster City, CA). Genotypes were called under standard conditions on a 
7900HT Real-time PCR instrument. All genotype calls were determined by two independent 
investigators, and only concordant calls were used. The average genotyping call rate was 
98.2%. The genotyping concordance rate among 849 replicate samples was 99.9%. There 
was no deviation in HWE for rs10242595, the only SNP analysed in this cohort.
Statistics
All SNPs were checked for HWE with χ2-analysis. LD between the SNPs was measured by 
D′ (Figure 1 for the IL6 and Figure 1S for the IL6R). We performed multiple linear 
regressions with total body fat mass for each SNP. Covariates for these calculations were 
determined as factors significantly associated with the primary outcome total fat in each 
cohort. Backward selection was then used to determine whether these covariates were 
suitable. Effect sizes and P-values for the remaining covariates are shown in Table 2S. 
Power calculations for the MrOS cohorts were based on the estimates for the two SNPs 
which were significantly associated with total fat mass in the GOOD cohort.
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Covariates in the GOOD cohort—Linear regression under the assumption of an 
additive model was used to analyze the relationships between total body fat mass and the 
SNPs (DD = 0, Dd =1, dd=2, where D and d are the major and minor alleles, respectively). 
Current physical activity and total body lean mass were used as covariates on log-
transformed response, in a similar way as done previously [(36, 37) Table 3 and Table 2S].
Covariates in the MrOS Sweden cohort—Linear regressions were performed 
assuming additive models for rs10242595 (GG = 0; AG =1; AA = 2) and for rs4075015 
(AA=0; AT=1; TT=2). Correction was made for study site (subjects were collected in three 
geographically separated regions), age, current physical activity, current smoking status and 
height. One limitation in the MrOS Sweden study is that the clinical sites used DXA 
machines from different manufacturers (see assessment of body composition above). In the 
multiple linear regression analysis we have used site as a covariate which to a large extent 
should compensate for this discrepancy. Moreover, when the subjects not measured with the 
Hologic DXA machine (i.e. MrOS Sweden from Uppsala and Malmö) were excluded from 
the calculation of combined elderly men (Table 4), the results remain very similar (see 
Results section). A sub-analysis with respect to type of DXA machine in MrOS Sweden 
could not be performed due to greatly reduced the sample size and power (not shown).
Covariates in the MrOS US cohort—Linear regression for rs10242595 was performed 
in a similar way as for MrOS Sweden. All covariates were the same as for MrOS Sweden 
with the addition of race. Information about effect sizes and standard errors (SEM), as well 
as confidence intervals (CI) and covariates used for adjustments in the three cohorts and the 
three cohorts combined are given in table legends (Table 3, Table 4 and Table 5).
Softwares—Haploview (v 4.1) was used for LD measurements, to generate figures 
representing LD-patterns in the IL6 and IL6R based on tag-SNP genotypes from the GOOD 
cohort, and for a haplotype analysis using case/control model. Haplotypes were also 
analyzed by sliding window approach using Helix Tree (v 7) (36). For linear and multiple 
linear regression analyses we used SPSS (v 17.0.0). Values are given as mean ± SD. All 
tests were two tailed and conducted at the 5% significance level.
Results
Characteristics of the SNPs in the IL6 and IL6R Genes
To investigate whether SNPs in the IL-6 system are associated with body fat, we analyzed 
several SNPs in the IL6 and IL6R genes in relation to the primary outcome total body fat 
mass as measured by DXA. We successfully genotyped 18 SNPs distributed across the IL6 
(n=8) and IL6R (n=10). The general SNP localizations within the genes, allele and genotype 
frequencies, and HWE are shown in Table 2 for the IL6 SNPs and in Table 1S for the IL6R 
SNPs. χ2 analysis showed no deviation from HWE for any of the 18 investigated SNPs. The 
allelic frequencies obtained are consistent with the dbSNP allelic frequencies for the 
European population.
Pair-wise LD tests between consecutive SNPs, genotyped in the GOOD cohort, showed that 
the LD (expressed as D′) was mostly strong and significant across the IL6 (also known as 
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interferon, beta 2). rs10242595, located about 2 kb downstream from the IL6 coding region, 
had weak LD with the other SNPs, with the exception for rs2069861 and rs1800795 (Figure 
1). In the IL6R gene, we could define two distinct LD-blocks (Figure 1S).
Associations between individual SNPs in the IL6 and IL6R and fat mass
The SNP associated with body fat close to IL6 was rs10242595 (effect size -0.11 SD units 
change per A allele, P=0.02, Pc = 0.19) with adjustment for covariates as presented in the 
legend of Table 3. In the IL6R gene, rs4075015 was associated with fat mass (effect size 
-0.09 SD units per T allele, P = 0.03, Pc = 0.17; Table 3S). Based on these estimates, the 
power to detect an association was approximately 95% in MrOS Sweden and >99% in 
MrOS US for both SNPs.
Replication of major findings in MrOS Sweden and MrOS US
Multiple linear regression analysis showed a borderline association between rs10242595*A 
and a decrease in the primary outcome total body fat mass (effect size -0.044 SD units/A 
allele, P=0.10 for the fully adjusted model; Table 4). There was no such association for the 
rs4075015*T (effect size 0.034 SD units/T allele, P=0.23, data not shown) and no further 
calculations were done on this SNP. Having found a borderline association between total 
body fat mass and rs10242595*A in the elderly Caucasian subjects of the MrOS Sweden 
cohort (n=2 851) we expanded the replication effort to include also the MrOS US cohort 
(n=5 609). The A allele of rs10242595 was significantly associated with low total body fat 
in the Caucasian subpopulation of the MrOS US cohort (effect size -0.047 SD units/A allele, 
P=0.009), and this was also seen in the MrOS US cohort as a whole (effect size -0.037 
units/A allele, P=0.03). rs10242595*A was significantly associated with decreased total 
body fat in combined elderly Caucasian men from MrOS Sweden and MrOS US cohorts 
(effect size -0.046 SD units/A allele, P=0.002) and in combined Caucasian men from 
GOOD, MrOS Sweden and MrOS US (effect size -0.052 SD units/A allele, P=0.0002). 
When only subjects measured with the Hologic DXA machine [(effect size -0.042, P=0.01 
in Caucasian subjects (n=5 994)] or only subjects measured with the Lunar Prodigy DXA 
machine [(effect size 0.048, P=0.006 in Caucasian subjects (n=3 046)] were included in the 
combined cohorts, similar results were obtained. In addition to the primary outcome total 
body fat mass, this analysis showed associations between the rs10242595*A variant and, 
decreases of secondary outcomes total fat %, body weight, body mass index (BMI), as well 
as for regional measures of fat (Table 5). There was also a negative correlation between the 
A allele and most of the fat related parameters in the GOOD study (data not shown). The A 
allele was associated with increased lean body mass in Caucasians in the combined MrOS 
Sweden and US Study (Table 5). However, there was no correlation between the A allele 
and lean body mass in the GOOD study (data not shown). The effect sizes for the different 
parameters, calculated as SD units per A allele, are also shown in Table 5. In the MrOS US 
Study a decrease in body weight by 0.03 SD units per A allele equals a body weight 
decrease of about 0.5% per A allele, or about 0.4 kg body weight per A allele for a man 
weighing 80 kg. There was no association between rs10242595*A on one hand and serum 
levels of insulin, glucose and fats on the other (data not shown).
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Haplotype analysis showed no association between IL6 or IL6R genes and body fat mass as 
calculated by case/control analysis or a sliding window approach (not shown).
Discussion
Although IL-6 is mostly associated with pathophysiologic adaptations during inflammation 
(1), there is evidence that endogenous IL-6 suppresses fat mass in healthy experimental 
animals (8-10). In this translational candidate gene study we performed a systematic 
investigation of how genetic variations in the IL6 and IL6R genes are associated with total 
body fat mass and regional fat parameters, as measured by DXA, in a well characterized 
population of 1 049 healthy young men within a two year age span. By using this approach, 
we identified one SNP (rs10242595) in the IL6 gene, not previously associated with any 
phenotypic changes, which was clearly associated with body fat mass and this observation 
was confirmed in two other cohorts consisting of in total 7 779 Caucasian elderly men.
As discussed above, IL-6 knockout mice develop obesity (8-10), but there are several other 
reasons to investigate possible associations between the IL-6 gene system polymorphisms 
and metabolic functions in humans. IL-6 belongs to the same family of proteins as leptin 
(38) and ciliary neurotrophic factor (CNTF), which both are known to suppress obesity. A 
variant of CNTF suppressed body fat in clinical phase 2 studies in humans, but the clinical 
development of CNTF as an anti-obesity drug was later discontinued due to technical 
problems with appearances of neutralizing antibodies to the drug (39). Moreover, IL-6 is 
released into the blood from adipose tissue in humans and there is a positive correlation 
between serum IL-6 levels and body fat (40, 41). IL-6 is also released from working skeletal 
muscle and has been suggested to be of importance for the metabolic adaptation to exercise 
(5, 42, 43). In resting lean individuals, the level of IL-6 may be higher in cerebrospinal fluid 
than in serum suggesting that IL-6 is also produced by the brain (14). Finally, the recent 
introduction of the IL-6 receptor antibody tocilizumab for treatment of autoimmune diseases 
makes it necessary to foresee possible side effects, including metabolic ones, after 
suppression of endogenous IL-6 (2, 3).
In earlier studies, several groups, including ours, found an association between the well 
described polymorphism in the IL6 promoter, -174G/C SNP (rs1800795), and BMI. 
However, this effect could not be confirmed in two large meta-analyses (20, 21) recently, it 
was reported by Qi et al. that certain haplotypes as well as some individual SNPs in the IL6 
gene were associated with BMI and waist circumference in two cohorts with about 3 000 
men and women in total (21). rs2069827, the individual SNP most associated with BMI in 
this study (21), was in strong LD (r2=0.92) with one of our tag SNPs (rs11766273, Tables 2 
and 3), but the latter was not associated with body fat mass in the young adult men from the 
GOOD study. The interrelation between the present IL6 gene polymorphism and the variants 
reported by Qi et al. and functional consequences of all of these polymorphisms need to be 
clarified. One possibility is that they are merely in LD with yet unknown functional 
polymorphisms. Some polymorphisms of the IL6R gene have also been associated with 
metabolic parameters (24-28). In the present study, we saw no reproducible associations 
between polymorphisms of the IL6R gene, including the non-synonymous rs2228145 (also 
known as rs8192284), and total body fat mass.
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There are some strengths and weaknesses of the present study. One strength is that the major 
finding of this study, significant association of rs10242595*A with decreased fat mass in 
young adult men, was replicated in two other population-based studies consisting of 7 779 
elderly Caucasian men. The statistical power increases not only thanks to the comparatively 
large sample, but also due to the fact that the cohorts are homogenous. Moreover, the fact 
that the effect size of the rs10242595*A on fat was similar (approximately -0.04 SD units/A 
allele) in each one of the two replication cohorts with men of similar age (MrOS Sweden 
and MrOS US) may support the validity of the present findings. The measurement of body 
fat with DXA is considerably more specific than the surrogate parameter BMI used in many 
other studies(29). As discussed above, the theoretical background for regarding IL6 as a 
candidate gene for obesity is strong. A clear drawback is that rs10242595 is likely to only be 
in LD with a functional polymorphism of the IL6 gene. However, it seems unlikely that 
rs10242595 is affecting another gene then IL6. The closest gene to rs10242595, besides IL6, 
is the translocase of outer mitochondrial membrane 7 homolog (yeast, TOMM7) gene that is 
located 81 kb 3′ of IL6. It would be important to determine if this association holds true in 
women and other ethnic groups as well. In the MrOS USA cohort there were no significant 
associations between the rs101242595 and body fat in comparatively small groups of non-
Caucasian subjects, but more detailed studies on considerably larger cohorts are needed to 
investigate this issue.
In summary, several earlier studies have indicated that IL-6 is important for metabolism. We 
now found that the IL6 polymorphism rs10242595*A, which has not been described to be in 
association with phenotypes earlier, is associated with decreased fat mass in three combined 
cohorts of 8 927 Caucasian men. The relation of the present data to possible metabolic side 
effects of IL-6 neutralizing therapy (2, 3) may be a topic of future investigation.
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Figure 1. 
The LD pattern of the interleukin 6 gene (IL6, also known as interferon, beta 2) based on 
results from tag-SNP genotyping in the GOOD cohort. The location of each tested SNP 
along the chromosome is indicated on top and the number in each square indicates the 
magnitude of linkage disequilibrium (LD) expressed as D′ between respective pairs of 
SNPs. Color scheme: bright red squares indicate strong LD (D′≈1); squares colored by 
lighter shades of pink indicate weaker LD; white color indicates very weak or no LD (D
′≈0). Modified from Haploview (37).
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TABLE 1
Characteristics of the study subjects
Table 1. Values are given as mean ± SD; n = number of subjects with both successful genotyping and 
available fat parameters.
Variables
GOOD
(n = 1 049)
MrOS Sweden
(n = 2 851)
MrOS US
(n = 5 611)
Age (yr) 18.9 ± 0.6 75.4 ± 3.2 73.7 ± 5.9
Height (cm) 181.4 ± 6.8 174.8 ± 6.5 174.1 ± 6.8
Weight (kg) 73.8 ± 11.9 80.6 ± 11.8 83.1 ± 13.2
Total fat (kg) 13.3 ± 8.0 22.1 ± 7.6 21.8 ± 7.1
Total lean tissue (kg) 57.4 ± 6.2 55.5 ± 6.8 58.0 ± 7.4
BMI (kg/m2) 22.4 ± 3.2 26.4 ± 3.5 27.4 ± 3.8
Trunk fat (kg) 6.8 ± 4.3 12.8 ± 5.0 12.3 ± 4.3
Arm fat (kg) 0.56 ± 0.41 1.12 ± 0.41 1.23 ± 0.49
Leg fat (kg) 2.5 ± 1.4 3.1 ± 1.1 3.0 ± 1.1
Total Fat (%) 17.2 ± 7.4 27.9 ± 6.9 26.2 ± 5.4
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TABLE 5
IL6 rs10242595 in relation to fat parameters in Caucasian elderly men from the combined MrOS cohorts
Table 5. Linear regression analysis of the associations between rs10242595 SNP and fat parameters in 
Caucasian elderly men from the combined MrOS cohorts. Data are mean with confidence intervals (CI). P-
values are calculated on log-transformed response (tissue fat mass measured by DXA) using linear regression 
under an additive model. Model I is adjusted for cohort and site, and Model II is adjusted for cohort, site, age, 
current physical activity, current smoking status, height, and total body lean mass.
Variables
MODEL I MODEL II
PP Effect size* (CI)
Total fat (kg) 0.005 -0.046 (-0.075 – -0.016) 0.002
Total fat (%) 0.006 -0.049 (-0.081 – -0.016) 0.003
Weight (kg) 0.02 -0.029 (-0.046 – -0.011) 0.002
BMI (kg/m2) 0.8 -0.033 (-0.053 – -0.015) 0.001
Lean body mass (kg)a 0.5 0.031 (0.005 – 0.056) 0.02
Trunk fat (kg) 0.01 -0.041 (-0.070 – -0.011) 0.007
Arm fat (kg) 0.0002 -0.065 (-0.095 – -0.034) 0.00003
Leg fat (kg) 0.006 -0.041 (-0.071 – -0.010) 0.009
a
Lean tissue mass not included as a covariate.
*
Effect size (regression coefficient) and SEM values are expressed as change in SD units (CI) per additional A (minor) allele and presented for the 
P2 model.
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